USTRx Act

HR 4780 (USTRx Act) creates a new Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative's office to address foreign government drug pricing policies. The bill requires annual reports assessing whether high-income countries' pharmaceutical pricing practices are unfair, non-market-based, or deny U.S. market access. If such practices are found, the USTR must submit a response plan within 30 days to Congress. This bill directly affects U.S. pharmaceutical manufacturers and consumers by aiming to ensure foreign governments pay their "fair share" for drug innovation developed in the U.S.